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Pseudohypoaldosteronism type II (PHA2) is a rare autosomal dominant form of volume-dependent low-renin
hypertension characterized by hyperkalemia and hyperchloremic acidosis but also by a normal glomerular filtration
rate. These features, together with the correction of blood pressure and metabolic abnormalities by small doses of
thiazide diuretics, suggest a primary renal tubular defect. Two loci have previously been mapped at low resolution
to chromosome 1q31-42 (PHA2A) and 17p11-q21 (PHA2B). We have now analyzed a new, large French pedigree,
in which 12 affected members over three generations confirmed the autosomal dominant inheritance. Affected
subjects had hypertension together with long-term hyperkalemia (range 5.2–6.2 mmol/liter), hyperchloremia (range:
100-109 mmol/liter), normal plasma creatinine (range: 63–129 mmol/liter) and low renin levels. Genetic linkage
was excluded for both PHA2A and PHA2B loci (all LOD scores at recombination fraction [v] 0), as wellZ ! 53.2
as for the thiazide-sensitive sodium-chloride cotransporter gene. A genome-wide scan using 383 microsatellite
markers showed a strong linkage with the chromosome 12p13 region (maximum LOD score , , atZ = 6.18 v = 0
D12S99). Haplotype analysis using 10 additional polymorphic markers led to a minimum 13-cM interval flanked
by D12S1652 and D12S336, thus defining a new PHA2C locus. Analysis of two obvious candidate genes (SCNN1A
and GNb3) located within the interval showed no deleterious mutation. In conclusion, we hereby demonstrate
further genetic heterogeneity of this Mendelian form of hypertension and identify a new PHA2C locus, the most
compelling and precise linkage interval described to date.
Introduction
The complex interplay between the many inherited and
environmental factors that regulate arterial blood pres-
sure makes it very difficult to identify the susceptibility
genes responsible for essential hypertension. Genetic
analysis of rare, severe Mendelian forms of hypertension
may facilitate this identification and open up new ave-
nues toward a better understanding of blood pressure
regulation (Lifton 1996).
Pseudohypoaldosteronism type II (PHA2), also
known as Gordon’s syndrome, is a volume-dependent
form of hypertension characterized by hyperkalemia,
hyperchloremic acidosis, and a normal filtration rate
(Arnold and Healy 1969; Gordon et al. 1970). The low
renin levels are thought to be due to volume repletion,
whereas plasma aldosterone is thought to vary accord-
ing to the contradictory influences of the plasma renin
and potassium concentrations (Gordon et al. 1995). The
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etiology of this disease is still unknown, but there is
some evidence for a primary renal defect along the distal
tubule. Affected patients are very sensitive to small
doses of thiazide diuretics, and the features of PHA2
are the mirror image of the Gitelman syndrome, in
which there are inactivating mutations in the thiazide-
sensitive sodium-chloride cotransporter gene (Simon et
al. 1996). The autosomal dominant inheritance of the
trait is suggested by the apparent transmission of PHA2
features from one parent to offspring in 110 families
(Gordon et al. 1995). Mansfield et al. (1997) studied
eight families, in which at least two subjects over two
generations were affected, and identified a 20–33-cM
PHA2A locus on chromosome 1 and a 21–43-cM
PHA2B locus on chromosome 17, assuming auto-
somal dominant inheritance. The locus on chromosome
17 was confirmed in another Australian kindred
(O’Shaughnessy et al. 1998) and is particularly inter-
esting, since it overlaps a region suggested to be linked
to human and rat essential hypertension (Julier et al.
1997).
We have now identified a new, large French family
with 12 individuals affected by PHA2 over three gen-
erations. We have used genetic markers mapped on
PHA2A and PHA2B loci to exclude these two loci and
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the involvement of the thiazide-sensitive sodium chlo-
ride cotransporter SLC12A3 gene. A genomewide scan
identified a new 13-cM PHA2C locus located on chro-
mosome 12.
Subjects and Methods
Pedigree
A large family from the north of France was identified
through a proband who had the typical features of
PHA2. We obtained informed consent from each par-
ticipant, or from the parents of the younger children,
and carried out a standard phenotypic analysis. It in-
cluded each subject’s medical history, a clinical exami-
nation with at least three manual blood pressure mea-
surements in sitting position, and basal biochemical
data. Following this examination, each individual found
to have high blood pressure level or hyperkalemia un-
derwent a second complete determination of the iono-
gram 1 wk later. Subjects were considered affected if
they were currently being treated for hypertension or
had persistent hyperkalemia ( mmol/liter) withK 1 5.2
normal plasma creatinine, high blood pressure (systolic
blood pressure 1160 mmHg or diastolic blood pressure
195 mmHg for adults, values above the 95th percentile
of those observed in childhood and adolescence in a
French population for offspring [Andre et al. 1982]).
Subjects were considered unaffected if they had normal
blood pressure and normokalemia. Others were consid-
ered undetermined.
Analysis of Candidate Loci
DNA was extracted from blood samples by conven-
tional techniques. All individuals with an unambiguous
phenotype (34/39) were genotyped using eight micro-
satellite markers spanning the PHA2A locus on chro-
mosome 1, six markers spanning the PHA2B locus on
chromosome 17, and three markers spanning the
SLC12A3 locus on chromosome 16, from the kit ABI
PRISM Linkage Mapping Set version 2 (PE Applied
Biosystems). Custom primers were designed to genotype
additional markers D16S408 and D16S494, which were
selected upon their map location in the vicinity of the
SLC12A3 gene and their heterozygosity. PCR reactions
were carried out in 7.5-ml volumes, containing 50 ng
genomic DNA, 1 # GeneAmp PCR buffer II (Roche
Molecular System), 2.5 mM MgCl2, 0.25 mM dNTPs,
0.33 mM each of both primers, and 0.3 U AmpliTaq
Gold DNA polymerase (Roche Molecular System). Al-
lele sizes were determined by separation on acrylamide
gels on an ABI 377 sequencer, and normalized to a con-
trol DNA sample CEPH 1347-02. Signal analysis and
genotype determination were automated using GENE-
SCAN 2.1 and GENOTYPER 1.1 software.
Genomewide Scan
Genotyping was performed by the Australian Genome
Research Facility using 383 autosomal microsatellite
markers of the kit ABI PRISM Linkage Mapping Set
version 2 (PE Applied Biosystems).
High-Resolution Mapping
Ten markers mapping to chromosome 12p13.3, be-
tween D12S352 and D12S336, and evenly distributed
through this linkage interval (D12S94, D12S91,
D12S100, D12S1626, D12S1652, D12S1725,
D12S1624, D12S314, D12S356, and D12S1623) were
analyzed in the 39 individuals of the family, using cus-
tom fluorescent dye-labeled primers and the protocol
described above. In order to avoid false-positive results
caused by genotyping errors, these markers were geno-
typed twice by two independent investigators (S.D.-N.
and I.D.).
Simulations, Linkage, and Haplotype Analyses
Transmission of the trait was assumed to be autosomal
dominant, with a disease-allele frequency of 0.005. Con-
servative and stringent models of inheritance were used,
as described by Mansfield et al. (1997). In the conser-
vative model, the phenocopy rate was set at 1% and
penetrance at 95%, whereas, in the stringentmodel, pen-
etrance was maximum with no phenocopies. The max-
imum expected LOD score was estimated by genotype
simulation: 900 replicates were generated using the
SLINK program (Weeks et al. 1990; Terwilliger and Ott
1994). Two-point LOD scores were then simulated using
the MSIM program. Simulated allele frequencies were
set at 0.3, 0.2, 0.2, 0.1, 0.1, and 0.1 (heterozygosity
0.8). Error checking on genotypic data was performed
using UNKNOWNprogram, and two-point LOD scores
were computed for the 383 markers by MLINK from
version 5.2 of the LINKAGE package (Terwilliger and
Ott 1994; Lathrop et al. 1985). Allele frequencies for
each marker were obtained online from the Genome
Database and were similar to those observed in our
white family. Recombination fractions were set to be
identical in males and females. Haplotype analysis and
pedigree drawing were performed with Cyrillic version
2.1 (Cherwell Scientific).
Mutation Screening
All exons of SCNN1A and GNb3 genes (GenBank
accession numbers Z92978–Z92981 and Y12048–
Y12058) were PCR amplified from the genomic DNA
of affected subject III.1 versus unaffected subject III.5,
by use of flanking intronic primers. Primer sequences are
available from authors upon request. Double-strand se-
quencing was performed using the dideoxy termination
304 Am. J. Hum. Genet. 67:302–310, 2000
method on an ABI 377 instrument (Prism Big Dye Ter-
minators Cycle Sequencing kit, PE Applied Biosystems).
Southern blots were performed using genomic DNA
from affected individual III.9 and unaffected individual
III.7, digested with HindIII, EcoRI, PstI and hybridized
with 32P-labeled cDNA probes (SCNN1A exon 3 and
GNb3 exon 11).
Results
Clinical and Biochemical Data
The family described here consists of 39 phenotyped
individuals, 12 of whom are considered to be affected
(table 1 and fig. 1). The proband III.1 was diagnosed as
hypertensive at age 37 years and was treated with a
combination of beta blockers and furosemide. Ten years
later, after having stopped his treatment for an unknown
period, he was hospitalized because of hypertension
(180/110mmHg) and hyperkalemia (6.2mmol/liter), de-
spite having a normal serum creatinine (120 mmol/liter).
Repeated measurements confirmed the typical biological
features of PHA2 (average values are indicated in table
1). Hydrochlorothiazide (50 mg) administered for 1 mo
normalized both blood pressure and plasma potassium.
A history of resistant hypertension and stroke in several
of his relatives led us to carry out a systematic clinical
and biochemical evaluation of the family (S. Disse-Ni-
code`me, X. Jeunemaitre, A. Fournier, P. Corvol, and J.-
M. Achard, unpublished data). As indicated in table 1,
10 subjects were considered to be clearly affected, since
they had (1) either high blood pressure or a history of
hypertension, (2) hyperkalemia in the absence of diu-
retics (range 5.2–6.2 mmol/liter), and (3) a tendency to-
ward hyperchloremia and acidosis. Two young subjects
(IV.6, age 28 years, and IV.10, age 18 years) were not
hypertensive but had typical biochemical features and
were also considered affected. The eight affected subjects
whose plasma renin and aldosterone concentrations
could be evaluated under satisfactory conditions, had
low renin levels and abnormally low aldosterone levels
with respect to the hyperkalemia (table 1). The disease
transmission over three generations and the number of
affected subjects in each sibship strongly suggested an
autosomal dominant inheritance.
Exclusion of PHA2A and PHA2B Loci
The SLINK and MSIM programs were used to esti-
mate the maximum power of linkage expected with 34/
39 members of the family. A maximum expected LOD
score was reached at recombination fractionZ = 7.17
(v) 0 with the stringent model (no phenocopy and 100%
penetrance), showing that the family could be infor-
mative. We used microsatellite markers of the 1q42-q44
and 17p21-q21 regions, corresponding to the PHA2A
and PHA2B loci, to test their implication in our fam-
ily. Linkage was significantly excluded with all pair-
wise LOD scores using both the conservativeZ ! 3.2
and the stringent model (table 2). We also tested five
markers at the thiazide-sensitive sodium-chloride co-
transporter SLC12A3 locus (GenBank accession num-
ber NM_000339 or X91220). Calculation of two-
point LOD scores (table 2), as well as multipoint LOD
score (data not shown) demonstrated exclusion of the
SLC12A3 locus under both genetic models.
Genomewide Scan
In the linkage analysis, 383 markers, representing all
autosomes, were used. Because they led to non-Men-
delian allelic segregation, 24 incorrect genotypes
(0.18%) were detected and were removed from the sta-
tistical analysis. With the stringent model, the LOD
scores were !2 for 374 markers (data not shown).
Eight markers gave non-significant positive results (data
available upon request). The maximum pairwise LOD
score was Zmax = 6.18 at from D12S99 (table 2).v = 0
The results were similar using the conservative model
with Zmax = 5.90 at from D12S99. The interval ofv = 0
positive linkage surrounding D12S99 spanned 22 cM
from pter to D12S336, for which linkage was clearly
excluded.
High-Resolution Mapping
We refined the linkage region by genotyping 10 ad-
ditional markers mapping within the linkage interval,
and calculating pairwise LOD scores.When the stringent
model was used, LOD scores were negative at forv = 0
the markers located in the region distal from D12S1725,
but were positive for all the markers located in the prox-
imal part of the locus, with a maximum value for
D12S1725 and D12S1623 (Zmax = 7.47 at ) (tablev = 0
2). We could not refine the linkage interval using the
conservative model. Haplotype analysis showed two re-
combination events in individuals III.23 and IV.12,
which allowed us to map the disease locus between
markers D12S1652 and D12S336 (fig. 1). This interval
on chromosome 12p13.3 (fig. 2), represents 13 cM on
the genetic map and was called PHA2C. The flanking
markers D12S1652 and D12S336 are both anchored on
the physical map constructed at the Albert Einstein Col-
lege of Medicine Human Genome Research Center.
Mutation Screening on Two Candidate Genes
Searches of the Genome Database and Online Men-
delian Inheritance in Man identified 32 genes of known
function, including the a subunit of the epithelial sodium
channel (SCNN1A) and the G protein beta-subunit type
3 (GNb3) (fig. 2). Southern blotting and direct sequenc-
ing of all the coding sequences of these two genes, were
Table 1
Clinical and Biochemical Features at Diagnosis of the Pedigree
SUBJECT ID SEX
BODY-MASS
INDEX
(kg/m 2)
AGE
(years)
AFFECTION
STATUSa
BLOOD PRESSURE
(mmHg)
HISTORY OF
HYPERTENSION
ANTIHYPERTENSIVE
TREATMENTb
K
(mmol/liter)
Cl
(mmol/liter)
HCO3

(mmol/liter)
CREATININE
(mmol/liter)
ACTIVE RENIN
(pg/ml)
ALDOSTERONE
(pg/ml)Systolic Diastolic
II.2 F 30 69 A 180 110 Y YT 4.4/6.2
c 104 31 102 … …
II.5 F 25 61 NA 150 85 N N 4.3 105 28 69 … …
II.6 F 19 64 A 180 100 Yd Y 5.5 106 25 87 2 105
II.8 F 18 70 A 120 70 Yd Y 5.6 107 27 91 … …
III.1 M 30 48 A 165 95 Y N 5.9 109 22 129 2 202
III.2 F 25 46 NA 135 80 N N 4.5 104 29 65 … …
III.3 M 28 50 A 130 70 Y YT 4.5 100 28 … … …
III.4 F 27 43 NA 145 85 N N 4.8 101 27 88 10 281
III.5 M 26 49 NA 120 80 N N 4.9 105 33 117 … …
III.7 M 26 43 NA 140 90 N N 4.4 104 35 106 … …
III.9 F 28 51 A 155 95 Y YT 4.4/5.2
c 104 29 118 5 202
III.10 F 24 42 U 120 80 N N 4.7 105 29 87 … …
III.11 M 26 34 NA 135 80 N N 3.7 104 33 131 … …
III.12 F 25 30 U 150 90 N N 4 99 28 65 … …
III.13 M 20 40 NA 140 90 N N 4.4 105 25 79 … …
III.14 M 25 30 U 160 100 Y N 4.4 101 32 103 … …
III.15 F 39 43 U 130 80 Y Y 4.6 104 30 65 … …
III.16 F 23 37 NA 110 70 N N 4.5 104 29 73 … …
III.17 F 20 24 NA 130 80 N N 4.5 103 30 64 … …
III.18 M 28 46 A 140 90 Y Y 5.3 107 26 93 5.5 223
III.19 F 21 45 NA 120 75 N N 3.7 104 31 69 … …
III.20 M 24 42 NA 150 90 N N 4.1 103 28 74 … …
III.21 M 23 43 NA 135 75 N N 4.2 103 27 106 … …
III.22 M 19 44 NA 135 85 N N 4.3 102 30 52 16 104
III.23 F 31 47 NA 120 80 N N 4.7 103 29 82 … …
III.25 F 18 41 A 155 100 Y N 5.5 106 26 63 2 191
IV.1 M 22 20 NA 125 75 N N 4.1 105 30 88 … …
IV.2 M 28 23 U 145 85 N N 4.2 103 28 … … …
IV.3 M 21 29 NA 130 80 N N 3.6 103 28 93 … …
IV.4 F 26 14 A 140 90 Y N 5.8 108 22 64 6 132
IV.5 M 21 16 NA 130 70 N N 4.4 101 26 98 … …
IV.6 M 20 28 A 120 70 N N 6.1 109 27 110 … …
IV.7 F 28 33 A 150 95 Y Y 5.2 106 27 72 … …
IV.8 F 21 32 NA 120 70 N N 4.2 99 33 106 … …
IV.9 F 23 30 NA 130 80 N N 4.4 102 26 85 … …
IV.10 M 20 18 A 130 90 N N 5.4 108 26 77 … …
IV.11 F 27 25 NA 135 85 N N 4.3 99 29 64 … …
IV.12 M 18 16 NA 120 70 N N 4.4 103 30 79 … …
IV.13 F 22 18 NA 115 65 N N 4.3 101 32 61 … …
a A = affected; NA = not affected; U = undetermined.
b YT = thiazide diuretics treatment.
c Washout value.
d Including a history of stroke.
Figure 1 Pedigree structure and haplotypes for the PHA2-affected family. Females are designated by circles and males by squares. Affected status is indicated by blackened symbols, unaffected
status by unblackened symbols, and undetermined status by grey symbols. Diagonal lines indicate deceased individuals. Genotypes for markers D12S352, D12S94, D12S91, D12S100, D12S1626,
D12S1652, D12S1725, D12S1624, D12S314, D12S99, D12S356, D12S1623, and D12S336 (telomere to centromere) are shown; inferred genotypes are shown in parentheses. The disease-associated
haplotype is indicated by red bars; a color change within a bar indicates the presence of a crossover event.
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Table 2
Pairwise LOD Scores
LOCUS
AND MARKER
STRINGENT LOD/CONSERVATIVE LOD AT v=
0 .01 .05 .1 .2 .3 .4
PHA2A:
D1S413 /8.55 12.65/8.15 8.12/6.83 5.86/5.04 3.05/2.70 1.52/1.37 .59/.54
D1S249 /9.61 15.77/9.09 9.60/6.94 6.36/4.95 3.14/2.62 1.49/1.29 .53/.47
D1S425 /9.78 15.32/9.03 8.04/6.09 5.06/4.10 2.41/2.06 1.15/1.01 .44/.39
D1S213 /6.00 9.57/4.97 4.86/3.23 2.99/2.18 1.36/1.07 .62/.51 .23/.19
D1S2800 /11.97 12.44/8.22 6.37/5.02 3.91/3.26 1.74/1.51 .72/.64 .21/.19
D1S2785 /6.37 7.97/5.19 4.63/3.41 3.16/2.39 1.48/1.19 .59/.48 .14/.11
D1S2842 /3.20 7.21/2.94 4.51/2.29 2.83/1.76 1.24/.94 .48/.39 .11/.09
D1S2836 /5.48 4.34/2.94 2.26/1.79 1.39/1.12 .49/.36 .07/.03 .02/.02
PHA2B:
D17S799 /11.71 14.96/8.14 7.77/5.03 4.77/3.38 2.07/1.60 .80/.63 .19/.14
D17S921 /10.20 12.60/7.15 7.39/4.57 4.61/3.11 2.03/1.52 .83/.65 .24/.18
D17S1857 /7.25 8.92/6.00 4.85/3.90 3.20/2.69 1.59/1.36 .68/.59 .18/.15
D17S798 /11.71 13.29/6.92 6.94/4.24 4.26/2.88 1.85/1.40 .72/.56 .17/.12
D17S1868 /6.47 7.35/5.06 3.82/3.07 2.36/1.99 1.06/.93 .47/.42 .18/.16
D17S787 /8.00 15.41/7.12 8.82/5.21 5.59/3.83 2.59/2.06 1.15/.97 .38/.33
SLC12A3:
D16S3068 /9.54 14.71/7.41 7.43/4.50 4.45/2.96 1.83/1.36 .67/.53 .15/.12
D16S3136 /7.73 14.26/7.51 8.41/5.73 5.44/4.05 2.64/2.19 1.24/1.09 .46/.41
D16S415 /7.26 10.66/5.80 5.25/3.65 3.09/2.34 1.20/.96 .36/.29 .01/.00
D16S408 /3.49 1.40/1.28 .72/.61 .44/.34 .19/.12 .08/.04 .02/.01
D16S494 /1.89 4.57/1.51 2.67/.98 1.82/.69 .98/.38 .52/.20 .21/.08
PHA2C:
D12S352 1.42/1.45 1.43/1.44 1.43/1.38 1.35/1.28 1.06/.98 .70/.63 .32/.29
D12S94 /2.04 1.46/2.06 1.93/2.04 1.92/1.92 1.57/1.51 1.04/.98 .46/.42
D12S91 /3.20 2.68/3.20 3.04/3.08 2.90/2.82 2.24/2.12 1.38/1.28 .47/.42
D12S100 /5.33 4.82/5.30 5.09/5.09 4.83/4.71 3.90/3.74 2.69/2.55 1.28/1.19
D12S1626 /4.57 3.97/4.55 4.35/4.39 4.16/4.07 3.35/3.22 2.28/2.16 1.04/.97
D12S1652 /4.10 3.58/4.09 3.92/3.95 3.75/3.67 3.03/2.90 2.07/1.94 .94/.87
D12S1725 7.47/7.13 7.36/7.01 6.87/6.54 6.24/5.93 4.86/4.60 3.32/3.11 1.59/1.48
D12S1624 2.12/2.01 2.09/1.99 1.98/1.88 1.82/1.72 1.46/1.37 1.04/.98 .56/.52
D12S314 4.25/3.98 4.19/3.92 3.92/3.67 3.55/3.31 2.71/2.51 1.76/1.62 .76/.69
D12S99 6.18/5.90 6.08/5.80 5.67/5.40 5.13/4.88 3.97/3.76 2.67/2.51 1.25/1.16
D12S356 4.43/4.20 4.35/4.13 4.03/3.82 3.62/3.42 2.73/2.57 1.76/1.64 .76/.70
D12S1623 7.47/7.13 7.36/7.01 6.87/6.54 6.24/5.93 4.86/4.59 3.32/3.11 1.59/1.47
D12S336 /.05 .80/.00 .10/.13 .10/.22 .24/.27 .22/.23 .14/.14
NOTE.—Pairwise LOD scores obtained at different recombination fractions. The genetic map in the vicinity of SLC12A3 locus
was estimated from the Location Database and the Genome Database: D16S3068-11 cM-D16S3136-8 cM-D16S415-.5 cM-
SLC12A3-.5 cM-D16S408-3 cM-D16S494.
performed in the proband (subject III.1) and one unaf-
fected subject (III.5). No deletion or deleteriousmutation
was found. A GrA substitution was found in the af-
fected subject at position 92 from initiation codon, in
the untranslated exon 1 of SCNN1A. This polymor-
phism was also present in 222 of 277 normotensive con-
trols. We also detected a R181W missense mutation in
exon 3 of SCNN1A, at the heterozygous state in the
unaffected control subject. Sequence analysis of exon 3
in the family showed that this polymorphism cosegre-
gated with the dark blue unaffected haplotype in figure
1. The only nucleotide variation found in theGNb3 gene
was the previously described C825T polymorphism. The
T allele was present in all affected subjects of the family,
but also in 13 unaffected subjects, demonstrating that
this allele was not the primary cause of PHA2.
Discussion
Although they have not yet revealed any major gene
implicated in essential hypertension, Mendelian forms
of hypertension in humans have contributed to a better
understanding of the molecular pathways underlying the
regulation of blood pressure. They should also make it
easier to identify novel candidate genes for more com-
mon forms of hypertension. Typical PHA2 is a rare dis-
order, and only a few sporadic cases and 13 families
containing 64 affected individuals have been described
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Figure 2 Ideogram of chromosome 12 (left). The linkage region
on 12p13.3 is expanded (middle) to show the markers used for the
haplotype analysis and their genetic distances (in cM) from each other.
PHA2C locus spans the D12S1652–D12S336 interval. The positions
of the main candidate genes belonging to the locus are shown (right).
KCNA1, KCNA5, KCNA6: voltage-dependent potassium channel
family members 1, 5, and 6; SCNN1A: amiloride-sensitive epithelial
sodium channel alpha subunit;GNb3: guanine-nucleotide bindingpro-
tein beta 3 subunit; USP5: ubiquitin specific protease 5.
so far (Gordon et al. 1995; Mansfield et al. 1997). The
genetic dissection of PHA2 is particularly interesting be-
cause of the extreme sensitivity of affected patients to
thiazide diuretics. This class of drug is widely used to
treat essential hypertension and reduces both blood pres-
sure and cardiovascular mortality and morbidity (World
Health Organization–International Society of Hyperten-
sion 1999). This particular sensitivity and the clinical
and biological characteristics of PHA2 suggest an ov-
eractivity of the thiazide-sensitive sodium-chloride co-
transporter. However, the pathophysiology of PHA2 is
likely to be more complex and several potential primary
defects have been proposed. These include (1) a specific
defect of the renal potassium secretory mechanism (Ar-
nold and Healy 1969; Brautbar et al. 1978) or a more
generalized cellular defect in transmembrane potassium
transport rather than an isolated renal tubular defect
(Farfel et al. 1978), (2) an abnormally increased rate of
chloride reabsorption by the tubule and an altered sen-
sitivity to mineralocorticoids (Schambelan et al. 1981),
and (3) an excessive renal sodium reabsorption proximal
to the site of aldosterone action (Gordon et al. 1970).
The discovery of two independent genetic loci causing
the disease (Mansfield et al. 1997) suggests that several
proteins that may or may not belong to the same path-
ophysiological pathway, may be involved.
We have now demonstrated further genetic hetero-
geneity with the mapping of a third locus at chromo-
some 12p13.3 responsible for PHA2. The PHA2C locus
is a 13-cM interval in which several genes may be po-
tential candidates, particularly two of them, SCNN1A
and GNb3. SCNN1A encodes the a subunit of the ami-
loride-sensitive epithelial sodium channel which is in the
distal nephron. Mutations affecting the structure of this
subunit, as well as those of the b and g subunits, can
cause pseudohypoaldosteronism type I (MIM 264350),
a salt-wasting syndrome in infancy (Chang et al. 1996),
whereas mutations affecting the proline-rich region of
the C-terminal part of either the b or g subunits cause
Liddle syndrome (Lifton 1996). Although this syndrome
is also an autosomal dominant form of hypertension in
which there is volume expansion, its biological features
are clearly different, with hypokalemia, alkalosis and
completely suppressed renin and aldosterone levels
(MIM 177200). GNb3 encodes the guanine nucleo-
tide-binding protein beta 3 subunit that may contrib-
ute to sodium transport through the membrane. Siffert
et al. (1998) described a 825 CrT polymorphism in
which the T allele was associated with a splice variant
in which nucleotides 498-620 of exon 9 were deleted.
This in-frame deletion could be responsible for the en-
hanced G-protein reactivity observed in the lympho-
blasts and fibroblasts from selected patients with essen-
tial hypertension.
We found neither deletion nor deleterious point mu-
tation in the coding and splicing consensus sequences
of the SCNN1A and GNb3 genes in our PHA2 family
by Southern blotting and direct sequencing. This anal-
ysis does not exclude variants in the noncoding regions,
especially in the 5′ regulatory sequences. Other genes in
the region may also be interesting candidates (fig. 2).
The USP5 gene is a member of the ubiquitin C-terminal
hydroxylase family which is involved in ubiquitin-de-
pendent proteolysis. Nonsensemutations causingLiddle
syndrome truncate the carboxyl terminus of SCNN1B
and SCNN1G implicated in the ubiquitin-dependent
degradation of the channel (Staub et al. 1996). A defect
in this pathway thus could be responsible for the ov-
eractivity of a channel regulating ion transport in kid-
ney. The KCNA1, KCNA5, and KCNA6 genes belong
to a cluster of potassium channels and are located at
the PHA2C locus. The encoded proteins have the char-
acteristic structure of voltage-gated ionic channels, with
six potential membrane-spanning segments. Defects in
one of these genes could be the primary cause of hy-
perkalemia in the affected subjects. However, the de-
layed rectifier function of KCNA potassium channels is
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generally associated with the repolarization of nerve
cells following an action potential, rather than with ion
transport in kidney, andmutations inKCNA1 have been
found to cause episodic ataxia type 1 (Browne et al.
1994). Finally, another autosomal dominant form of
hypertension has been mapped to chromosome 12p
(Schuster et al. 1996). However, there are no particular
biochemical features associated with this disease and
the corresponding locus is more centromeric. Future de-
termination of the molecular basis of PHA2 should lead
to the identification of a possible new molecular path-
way involved in blood pressure regulation and of new
therapeutic targets in arterial hypertension.
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